Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026
Enrico Ferro, Electrophysiology Fellow at Beth Israel Lahey Health, Clinical Investigator at Richard A. and Susan F. Smith Center for Outcomes Research, shared on LinkedIn:
”It was great to present our latest study at EHRA 2026 in Paris for the Young Investigator Award.
We ran one of the largest comparative safety analyses of PFA vs radiofrequency ablation for AF, performed at Beth Israel Deaconess Medical Center (large volume, tertiary care center, >1,500 PVI per year).
- Large study cohort of ~4,000 patients (2,000 PFA vs 2,000 RF);
- 2 strokes (0.1%) in the RF arm (2022-2024);
- 10 strokes (0.5%) in the PF arm (2024-2026);
- Strokes were not clustered at the time of PF adoption. They were evenly distributed throughout the study period;
- There was no correlation between strokes and physician experience or procedural volume – there was no learning curve effect;
- We report stroke rates with other commercial PFA platforms beyond Farapulse, with a sizable amount of Sphere 9 cases (~500 pts);
- These data show a uniform stroke rate across PFA platforms (~0.4%) and preliminarily suggest a possible PFA class effect.
- Of note, posterior wall isolation was performed in 60% of PF cases, vs only 30% of RF cases. As expected, there is more extensive ablation with PFA, and we need to accrue more stroke events to power a mediator model and understand if more extensive ablation may explain the higher stroke rate.
In summary, our study found that the modern ‘PFA strategy’ seems associated with a significantly higher stroke risk, compared to the ‘RF strategy’.
As we accrue events and increase power, we will re-run the model to understand which specific element(s) of the PFA strategy may explain the high observed stroke rate.
Stay tuned!”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026